Market Overview
The CNS biomarkers market covers diagnostic and research-grade assays, platforms, and services that measure biological indicators of central nervous system health and disease. It spans multiple biomarker classes, including protein-based markers (such as amyloid-beta and tau), neurofilament light chain, genetic and epigenetic markers, and neuroimaging-derived digital biomarkers. Valued at roughly USD 5.41 billion in 2025, the market is set to nearly double by 2030 as neurodegenerative disease prevalence rises worldwide and diagnostic pathways are modernized.
- •Estimated 2025 market value: USD 5.41 billion, with forecasts indicating expansion to roughly USD 10-11 billion by 2030.
- •Forecast CAGR through 2030: approximately 12.3%, among the highest growth rates in clinical diagnostics.
- •Core applications span Alzheimer's disease, Parkinson's disease, multiple sclerosis, stroke, traumatic brain injury, and CNS oncology.
Growth Drivers
Rising global incidence of neurodegenerative and neuropsychiatric disorders is the primary growth catalyst, supported by aging populations in North America, Europe, and parts of Asia-Pacific. Pharmaceutical and biotech investment in CNS drug pipelines has intensified demand for companion diagnostics and patient stratification biomarkers, particularly as disease-modifying therapies for Alzheimer's reach the market. Technological advances in immunoassays, mass spectrometry, next-generation sequencing, and high-sensitivity blood-based detection are also reducing reliance on invasive lumbar punctures and expanding clinical adoption.
- •Aging demographics are increasing the prevalence of Alzheimer's, Parkinson's, and related dementias, expanding the addressable diagnostic population.
- •Regulatory approvals of disease-modifying Alzheimer's therapies (such as anti-amyloid antibodies) are creating demand for amyloid and tau biomarker testing.
- •Improvements in assay sensitivity are enabling blood-based and CSF-based biomarkers to replace or complement PET imaging in clinical workflows.
Segmentation and Regional Analysis
By type, the market is segmented into genomics, proteomics, metabolomics, and imaging biomarkers, with proteomics currently dominating due to widespread use of protein-based assays. By application, Alzheimer's disease and other dementias account for the largest share, followed by Parkinson's disease, multiple sclerosis, and CNS cancers. North America leads global revenue, supported by strong research funding, high disease awareness, and a concentration of diagnostic companies; however, Asia-Pacific is the fastest-growing region due to expanding healthcare infrastructure and rising neurological disease burden.
- •Disease application: Alzheimer's disease holds the largest share, followed by Parkinson's, multiple sclerosis, and CNS oncology.
- •End users: Hospitals, diagnostic laboratories, academic and research institutes, and pharmaceutical/biotech sponsors of CNS trials.
- •Regional leaders: North America remains the largest market; Asia-Pacific is projected to record the fastest CAGR through 2030.
Trends and Outlook
What are the recent trends and outlook?
The most transformative trend is the shift from cerebrospinal fluid and PET imaging-based biomarkers to accessible blood-based assays, which promise earlier detection and population-scale screening for Alzheimer's and other neurodegenerative diseases. Integration of artificial intelligence and machine learning into biomarker discovery, digital cognitive assessments, and multi-omics data interpretation is also accelerating the development of composite biomarker panels. With continued regulatory momentum behind companion diagnostics and growing payer recognition of biomarker-guided treatment, the CNS biomarkers market is positioned for sustained double-digit growth through 2030.
- •Blood-based biomarkers (including p-tau217, p-tau181, GFAP, and neurofilament light chain) are transitioning from research use into routine clinical practice.
- •AI-enabled biomarker discovery and multimodal data integration are accelerating development of predictive and prognostic CNS signatures.
- •Reimbursement expansion for biomarker-guided Alzheimer's diagnosis is expected to further unlock clinical demand over the forecast period.
Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.
Connect to an analyst →Market size and forecast are Claight Analysis, informed by public research and industry data. Historical years before 2025 and all forecast years are Claight estimates at the stated CAGR. Retrieved 2026.